| Literature DB >> 29348476 |
Maximilian Kleinert1,2,3,4, Christoffer Clemmensen1,2,3, Susanna M Hofmann3,5,6, Mary C Moore7, Simone Renner3,8, Stephen C Woods9, Peter Huypens3,10, Johannes Beckers3,10,11, Martin Hrabe de Angelis3,10,11, Annette Schürmann3,12, Mostafa Bakhti3,5,13, Martin Klingenspor14,15,16, Mark Heiman17, Alan D Cherrington7, Michael Ristow18, Heiko Lickert3,5,13, Eckhard Wolf3,8, Peter J Havel19, Timo D Müller1,2,3, Matthias H Tschöp1,2,3.
Abstract
More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.Entities:
Mesh：
Year: 2018 PMID： 29348476 DOI： 10.1038/nrendo.2017.161
Source DB: PubMed Journal: Nat Rev Endocrinol ISSN： 1759-5029 Impact factor: 43.330